ClinicalTrials.gg
Active, not recruitingNCT06188702Updated Oct 13, 2026

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Phase 1/2 interventional study of S095035 and TNG462 in MTAP-deleted Solid Tumors, sponsored by Servier Bio-Innovation LLC. Active, not recruiting at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 13, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.

Enrollment
75th of 140
61 · median 75
Started
2024
with 12 others
Phase 1/2
31 of 155
14 open now
Primary completion
2027-05
later than 22 of 66 live
Registered
122nd of 155
by date

Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 75th largest by enrollment of the 140 interventional ones that give a count, is one of 13 that started in 2024, is one of 31 in phase 1/2, reaches primary completion later than 22 of the 66 other live ones, and was the 122nd registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Biliary Tract Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A [MAT2A] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 [PRMT5] inhibitor.

03

Conditions studied

  • MTAP-deleted Solid Tumors

Keywords

  • MAT2A
  • MTAP
  • Solid Tumors
  • PRMT5
  • SAM
  • Synthetic Lethality
  • MTAP deletion
  • MAT2A Inhibitor
  • Advanced Solid Tumors
  • Biliary Tract Cancer
  • Non-small Cell Lung Cancer
  • Pancreatic Adenocarcinoma
  • Gastroesophageal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Estimated ≥3 months.
  • PS 0-1
  • Participants able to comply with highly effective method of requirements.
  • Participants with confirmed advanced or solid tumor's (excluding central nervous system tumors other than IDHwt glioblastoma), with as per 1.1 or RANO 2.0 criteria for participants with IDHwt glioblastoma, that have progressed after at least one prior treatment regimen given for advanced/metastatic disease, and for whom additional effective standard therapy is not available. Patients in China with IDHwt glioblastoma will not be included.
  • Participants with pre-existing documented MTAP homozygous gene deletion in their tumor tissue, determined using a next generation sequencing in vitro diagnostic test prior to screening.
  • Phase 1 only - Participants (except IDHwt glioblastoma) willing to undergo paired fresh (pre-treatment and on-treatment) procedure. Exceptions may be made for feasibility and safety concerns. IDHwt glioblastoma must provide archival tissue from most recent surgery or biopsy.
  • Adequate organ functions.
  • Phase 2 only - Participants in dose expansion, except those with IDHwt glioblastoma, must provide newly collected tumor biopsies at screening. If not medically feasible archival tissue may be used, provided it was collected within 3 months before study entry and no treatment has been received since the most recent biopsy.
  • Phase 2 only - Participants with IDHwt glioblastoma must provide archival tissue from their most recent surgery or biopsy, collected before screening.
  • Phase 2 only - Participants in China who are to be considered for enrollment in the single agent dose expansion Arms and who have a pre-existing, documented cyclin-dependent kinase inhibitor 2A (CDKN2A) homozygous gene deletion in their tumor tissue (confirmed by an NGS IVD test), but do not have homozygous MTAP deletion reported, will need to be pre-screened to confirm homozygous MTAP deletion. Pre screening for homozygous MTAP deletion will be conducted using a central NGS IVD test using an archival tumor tissue, preferably the most recent and not older than 3 years.
  • Phase 2 Arm 1a only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with homozygous deletion of MTAP, with measurable disease as per RECIST version 1.1, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 1b only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced BTC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 1c only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced PDAC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 1d only - Participants with any other locally advanced or metastatic with homozygous deletion of MTAP, who have received and progressed of experienced recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 2a only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced BTC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 2b only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced gastroesophageal cancer with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
  • Phase 2 Arm 2c only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced PDAC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.
  • Active second primary other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.
  • Known prior severe to any component of the study drug formulation.
  • Major surgery within 4 weeks prior to the first study drug administration or participants who have not recovered from side effects of the surgery.
  • Have a known history of Gilbert's syndrome.
  • Participants with a known cardiovascular disease or condition.
  • Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.
  • Active .
  • Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of study drug
  • Pregnant or lactating women.
  • Women of who have a positive pregnancy test within 7 days prior to the first day of study drug administration.
  • History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to first study drug intake.
  • Severe or uncontrolled active acute or chronic infection.
  • Participants who have already received a MAT2A or PRMT5 inhibitor.
  • A medical condition that results in increased clinically significant photosensitivity (e.g., solar urticaria, lupus erythematosus, etc.).
  • Participants who are scheduled to receive the S095035-TNG462 combination, with a known clinically significant ophthalmologic disease, including:
  • Prior history of drug-induced or toxic retinopathy or optic neuropathy
  • Uncontrolled glaucoma
  • Pre-existing macular degeneration
  • Ongoing Grade ≥2 retinopathy, optic neuropathy, or optic neuritis
  • Other known active retinal pathology
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Phase 1 Arm 1 - S095035 single-agent dose escalation

    Drug: S095035

  • Experimental
    Phase 1 Arm 2 - S095035-TNG462 combination dose escalation

    Drug: S095035 · Drug: TNG462

  • Experimental
    Phase 2 Arm 1a NSCLC - S095035 single-agent dose expansion

    Non-Small Cell Lung Cancer

    Drug: S095035

  • Experimental
    Phase 2 Arm 1b BTC - S095035 single-agent dose expansion

    Biliary Tract Cancer

    Drug: S095035

  • Experimental
    Phase 2 Arm 1c PDAC - S095035 single-agent dose expansion

    Pancreatic Ductal Adenocarcinoma

    Drug: S095035

  • Experimental
    Phase 2 Arm 1d Basket arm - S095035 single-agent dose expansion

    Drug: S095035

  • Experimental
    Phase 2 Arm 2a BTC - S095035-TNG462 combination dose expansion

    Biliary Tract Cancer

    Drug: S095035 · Drug: TNG462

  • Experimental
    Phase 2 Arm 2b Gastroesophageal - S095035-TNG462 combination dose expansion

    Drug: S095035 · Drug: TNG462

  • Experimental
    Phase 2 Arm 2c PDAC - S095035-TNG462 combination dose expansion

    Pancreatic Ductal Adenocarcinoma

    Drug: S095035 · Drug: TNG462

Interventions

  • DrugS095035

    S095035 will be taken orally every day in 28-day cycles.

  • DrugTNG462

    TNG462 will be taken orally every day in 28-day cycles.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicities (DLTs)

    Phase 1 only

    Time frame: Through cycle 1 (each cycle is 28 days)

  2. Total number of adverse events (AEs)

    Phase 1 only

    Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years

  3. Total number of serious adverse events (SAEs)

    Phase 1 only

    Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years

  4. Objective response rate (ORR)

    Phase 2 only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment and by blinded independent central review (BICR)

    Time frame: Through the end of the study (approximately 5 years)

Secondary outcomes

  1. Area under the concentration-vs-time curve (AUC) from 0 to time of last measurable concentration (AUC0-t)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  2. AUC from 0 to infinity (AUC0-∞)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  3. AUC over 1 dosing interval at steady state (AUCtau,ss)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  4. Time to maximum concentration (Tmax)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  5. Maximum concentration (Cmax)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  6. Trough concentration (Ctrough)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  7. Half-life (t½)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  8. Apparent volume of distribution (Vd/F)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  9. Apparent clearance (CL/F)

    Phase 1 and 2

    Time frame: Through the last dose of study treatment (approximately 5 years)

  10. Change from baseline in plasma concentrations of S-adenosylmethionine (SAM) and/or tumor symmetric dimethylarginine (SDMA) residues during treatment

    Phase 1 only

    Time frame: Through the last dose of study treatment (approximately 5 years)

  11. Objective response rate (ORR)

    Phase 1 only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment

    Time frame: Through the end of the study (approximately 5 years)

  12. Best overall response (BOR)

    Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2.

    Time frame: Through the end of the study (approximately 5 years)

  13. Clinical benefit rate (CBR)

    Phase 1 and 2; CBR=complete response \[CR\]+partial response \[PR\]+stable disease \[SD\] ) ≥6 months, Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2

    Time frame: Through the end of the study (approximately 5 years)

  14. Duration of response (DOR)

    Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2. The time from date of first documented confirmed CR or confirmed PR to date of first documented disease progression or death due to any cause.

    Time frame: Through the end of the study (approximately 5 years)

  15. Time to response (TTR)

    Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2. The time from the date of randomization to date of first documented confirmed complete response (CR) or confirmed partial response (PR).

    Time frame: Through the end of the study (approximately 5 years)

  16. Progression-free Survival (PFS)

    Phase 2 Only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as assessed by investigator and by BICR

    Time frame: Through the end of the study (approximately 5 years)

  17. Overall Survival (OS)

    Phase 2 Only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as assessed by investigator and by BICR

    Time frame: Through the end of the study (approximately 5 years)

  18. Total number of adverse events (AEs)

    Phase 2 Only

    Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years

  19. Total number of serious adverse events (SAEs)

    Phase 2 Only

    Time frame: Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years

  20. Number of dose interruptions

    Phase 2 Only

    Time frame: Through the last dose of study treatment (approximately 5 years)

  21. Number of dose reductions

    Phase 2 Only

    Time frame: Through the last dose of study treatment (approximately 5 years)

  22. Dose intensity

    Phase 2 Only

    Time frame: Through the last dose of study treatment (approximately 5 years)

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2027, 36 months after the start.

Of 48 phase 1/2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 68. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 3, 2024
StartActual
Apr 29, 2024
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
60→61
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Enrollment 60→61
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06188702
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier, Tango Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 3, 2024
Start date
Apr 29, 2024
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion